Clinical Trial Update: Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. [Phase 1]

View source ↗

Summary

Arovella Therapeutics reports a Phase 1 study of ALA-101 in CD19-positive Non-Hodgkin lymphoma and leukemia; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• ALA-101

Snippet

Sponsor: Arovella Therapeutics Ltd | Conditions: Non Hodgkin Lymphoma (NHL), Leukaemia | Phase 1 | Status: NOT_YET_RECRUITING